SeraCare Life Sciences Inc announces three presentations at the Clinical Virology Symposium held April 19-22, 2009 in Daytona Beach, Fla based on scientific data generated in the Company’s research programs.
These data support SeraCare’s plans to expand their diagnostic controls product portfolio later this year with a new genotype panel for human papillomavirus, the virus that can lead to cervical cancer, and a suite of quality controls to support testing for the sexually transmitted diseases (STDs) chlamydia and gonorrhea.
“Testing for STDs is the largest and fastest growing segment of molecular diagnostics today and, given SeraCare’s longstanding expertise in the development of quality controls, we intend to play a leadership role in this area,” said Susan Vogt, President and CEO of SeraCare. “SeraCare has focused its scientific efforts on high-value areas that will drive the introduction of a number of new offerings in 2009, including those in the STD arena. These new products will not only play an important role in the accurate testing and treatment of multiple diseases, but also will also support the Company’s near-term goal of achieving and sustaining enhanced cash flow and operating profitability.”
Posters presented by SeraCare scientists Dr Bharathi Anekella, Dr Renee Howell and Dr Patricia Garrett at the Clinical Virology Symposium included:
- Development of an HPV Genotype Panel for Evaluation of Multiple Test Platforms”
- Platform Specific Quality Controls for Nucleic Acid Tests for Chlamydai Trachomatis (CT) and Neisseria Gonorrheae (NG)”
- 20 Years of Research and Development Experience with HIV, HCV and HBV Seroconversion Panels”
Source: Seracare Life Sciences Inc